@article{afb35b4f5acb41b9af8234f0a80d96bd,
title = "Provider understanding of the 2013 ACC/AHA cholesterol guideline",
abstract = "Background Providers' understanding of the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guideline in clinical practice is not known. Methods We designed a questionnaire, which was administered to internal medicine, family practice, cardiology, and endocrinology providers at 21 venues across the United States. We compared responses between providers in training or practice and between specialists (cardiology and endocrinology) and nonspecialists (internal medicine and family practice). Results Response rate was 72.1% (543 of 725). About 43% of the providers in training and 48% of those in practice indicated having read the guideline. Almost 50% in each group were unable to identify the 4 statin benefit groups and a large proportion (41% in training and 49% in practice) were not aware of the ≥7.5% 10-year risk threshold for discussion regarding statin therapy. Most (∼85%) were unaware of the 4 outcomes assessed by the 10-year ASCVD risk equation. About 36% of the providers in training and 48% in practice could identify a patient with familial hypercholesterolemia and start a discussion regarding statin therapy. Only 27.6% of the providers in training and 40.4% in practice recommended repeating a lipid panel 6-8 weeks after starting statins in a patient with recent myocardial infarction. Similar gaps were noted when comparing specialists to nonspecialists. Conclusion Most providers do not completely understand the 2013 ACC/AHA cholesterol guideline. As an unintended consequence, providers are moving away from lipid testing to document response and adherence to statin therapy. Efforts are needed to address these gaps.",
keywords = "ASCVD risk, Cholesterol guideline, Familial hypercholesterolemia, Practice, Survey",
author = "Virani, {Salim S.} and Yashashwi Pokharel and Lynne Steinberg and Winston Chan and Akeroyd, {Julia M.} and Gowani, {Saqib Ali} and Ankur Kalra and Venkateshwar Polsani and Miedema, {Michael D.} and Jones, {Peter H.} and Vijay Nambi and Petersen, {Laura A.} and Ballantyne, {Christie M.}",
note = "Funding Information: Dr Ballantyne received grant/research support which are all significant. (All paid to institution, not individual): Abbott Diagnostic, Amarin, Amgen, Bristol-Myers Squibb, Eli Lilly, Esperion, Merck, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda Development Centers of America, NIH, AHA, ADA. Consultant—Abbott Diagnostics, Amarin, Amgen*, Astra Zeneca*, Eli Lilly, Esperion, Genzyme, Matinas BioPharma Inc, Merck*, Novartis, Pfizer*, Regeneron, Sanofi-Synthelabo. *Significant where noted (>$10,000); remainder modest (<$10,000). Dr Jonesis a scientific advisory board member for Merck, Amgen, and Sanofi/Regeneron and the Chief Science Officer for the NLA. Dr Nambi is a member of regional advisory board for Sanofi Regeneron. He is a co-investigator on patent filed along with Roche diagnostics for use of biomarkers in prediction of heart failure. He received grants from Gulf Coast Medical Foundation, Gillson Longenbaugh Foundation, and Department of Veterans Affairs. The remaining authors have nothing to disclose. Funding Information: This work was supported by Baylor College of Medicine Academy of Distinguished Educators Fulbright & Jaworski L.L.P . Educational Grant. Dr. Virani is supported by the American Heart Association Beginning Grant-in-Aid (14BGIA20460366) and the American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44). This work was also supported by the Houston VA HSR&D Center for Innovations grant (grant HFP 90-020 ). ",
year = "2016",
month = may,
day = "1",
doi = "10.1016/j.jacl.2015.11.002",
language = "English",
volume = "10",
pages = "497--504.e4",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "3",
}